{
  "docId": "019dd923-5ca1-7489-b639-45501f4b359b",
  "docSlug": "158df8627a0b9aca",
  "documentTitle": "Opioid Conflicts Majority Staff Report",
  "authorId": "McKinsey",
  "authorName": "U.S. House Committee on Oversight and Reform",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 43,
  "pageCount": 53,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "appendix_disclosure",
  "function": "cite_precedent",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "This slide appears to be from a report or legal document detailing McKinsey's involvement with Purdue Pharma, specifically focusing on the 'ADF Strategy'.",
  "elementsJson": [
    "paragraph",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/43",
  "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-43",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "One really powerful move could be to require that all opioids reimbursed by HHS must have abuse deterrent formulations.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-cdec-74db-b49d-7436cc412f5f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "Despite expressing a concern that McKinsey should “drive the debate with data and facts,” in a subsequent email and having previously participated on Purdue matters himself, Mr. Singh stated: “I am happy to take the pen and make some line edits to stress these areas.”206 It is unclear what line edits Mr. Singh made.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3198a323-0c9f-4373-a3ca-2a46c990cc79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.78,
        "x": 0.11,
        "y": 0.73
      },
      "kind": "paragraph",
      "text": "Specifically, since 2014, McKinsey and Mr. Ghatak had pushed what the firm referred to as the “ADF Strategy” at Purdue. Under McKinsey’s recommendation, Purdue would submit an",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52bd451d-430c-456b-bf5e-aecef71642ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "Mr. Ghatak then suggested adding caveats in the memo that would shift focus away from opioid manufacturers, noting that the opioid crisis “is not purely about prescription drugs, a large part of it involves heroin.” Mr. Ghatak stated, “I think it is important to acknowledge that the opioid crisis is multi-factorial,” and he continued, “In fact, think we could suggest a big data approach to better understanding these issues so the root issues can be addressed.”208",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e621843-8974-45bd-bcdc-566c92558fb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.78,
        "x": 0.11,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "In the internal email transmitting his feedback to his McKinsey colleagues, Mr. Ghatak stated, “First for disclosure, I serve a manufacturer of opioids.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e1a46d0-7199-4237-94de-9ba6c0cc1e30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.43
      },
      "kind": "paragraph",
      "text": "Mr. Ghatak also suggested edits shifting the blame for the crisis away from his client’s drug, OxyContin, and onto generic formulations, noting that “the vast volume of prescriptions (90%+) are actually generics and many of the branded ones now have abuse deterrent properties but the generics don’t.” Mr. Ghatak proposed: “One really powerful move could be to require that all opioids reimbursed by HHS must have abuse deterrent formulations.”209",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a462270a-3db1-410a-bc6f-d5e9aa275685",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.11,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Despite Mr. Singh’s warning, the following day Mr. Ghatak, who had led more than 30 engagements at Purdue and was working on a Purdue contract at this time, provided extensive feedback on the Azar memo that would appear to strongly benefit his clients in the opioid industry.207",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1041311-0fa3-43f6-ac5b-9d67460f2b00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.78,
        "x": 0.11,
        "y": 0.67
      },
      "kind": "paragraph",
      "text": "Mr. Ghatak’s recommendation to convert the opioid market to branded, “abuse deterrent” formulations appeared to align with a long-standing priority of McKinsey’s work for Purdue, intended to stave off generic competition for OxyContin.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f10f3a1e-6f4f-4ba9-b348-71ea4a2f3368",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.66,
        "x": 0.17,
        "y": 0.53
      },
      "kind": "quote",
      "text": "“One really powerful move could be to require that all opioids reimbursed by HHS must have abuse deterrent formulations.” McKinsey Senior Partner Arnab Ghatak, January 2018",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "216d1fbc-d239-43e2-8b72-527dacb18682",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "One really powerful move could be to require that all opioids reimbursed by HHS must have abuse deterrent formulations. — McKinsey Senior Partner Arnab Ghatak, January 2018",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-cdec-74db-b49d-7a57a760d975",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.81
      },
      "kind": "source-note",
      "text": "206 MCK-HCOR-0179997.\n207 MCK-HCOR-0174550 to MCK-HCOR-0174698 (McKinsey Purdue Engagement List).\n208 MCK-HCOR-0179910, Page 2.\n209 Id.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7fb39e1-dad5-4687-915a-bb447cbe4b0f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 53,
      "from": 29,
      "beatId": "1170eac2-9202-4b41-a53c-edbd934ded10",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document concludes with implications of McKinsey's actions and potential next steps for regulatory action.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 53,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033",
      "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}